Search results
British patients test world’s first personalised mRNA jab for melanoma
Press Association News via AOL· 2 days agoThe therapy combination is also being trialled in lung, bladder and kidney cancer. One of the first...
Merck Stock Jumps After Dow Jones Stalwart Rides Its Cancer 'Star' To Another Quarterly Beat
Investor's Business Daily· 3 days agoMerck stock popped Thursday after the Dow Jones stalwart topped Wall Street's first-quarter views on...
Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda
Reuters via Yahoo Finance· 3 days ago(Reuters) -Merck & Co on Thursday raised its annual profit and revenue forecasts on the back of...
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 4 days agoOverall, 27.3% responded to the treatment. A total of 63.6% of patients had their disease under...
Treatment Options for HER2-Negative Breast Cancer
Healthline· 4 days agoMost breast cancers are HER2-negative. There are many treatment options for this type of breast cancer. Your treatment
British man tests first personalised melanoma vaccine
BBC via Yahoo News· 2 days agoHospitals (UCLH) doctors are giving it alongside another drug, pembrolizumab or Keytruda, that also...
Merck shares target raised on strong Q1 performance By Investing.com
Investing.com· 3 days agoOn Thursday, Truist Securities adjusted the stock price target for Merck (NYSE:MRK), a global...
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
CNBC· 3 days agoMerck on Thursday reported first-quarter revenue and adjusted earnings that topped expectations as...
U.K. Tests World-First Personalized Skin Cancer Vaccine
Forbes· 2 days agoBritish patients are trying a first-of-its-kind customized vaccine for skin cancer as part of a...
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
Morningstar· 4 days agoMedia Release Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma patients who do not express PD-L1 (TACTI-003, Cohort B) shows ...